ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer

Zhou, Jia-Ying; Liu, Si-Yang; Wu, Yi-Long*
Expert Opinion On Drug Safety2020-5-3DOI: 10.1080/14740338.2020.1753697
12被引12阅读
引用收藏
分享

摘要

Introduction: Lung cancer is the most prevalent malignant tumors worldwide. Over the past decade, the emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has ushered in a new era of lung cancer treatment. Therefore, clinical trials investigating the efficacy and safety of these drugs are important. Areas covered: This review provides an overview on the safety of three classes of EGFR-TKIs and discusses the adverse events (AEs) and reactions reported in the literature. Expert opinion: EGFR-TKIs significantly improve progression-free survival and overall survival in non-small cell lung cancer (NSCLC) patients with an activating mutation of EGFR. However, EGFR-TKIs also block the EGFR-regulating pathways in the skin and gastrointestinal tract and cause AEs, including diarrhea, liver toxicity, skin disease, stomatitis, interstitial lung disease, and ocular toxicity, which have detrimental effects on quality of life and drug compliance. Clinicians should understand how to prevent and control these adverse reactions, which can often be achieved by dose reduction, discontinuation of treatment, or switching to another drug.

学科与关键词

关键词
Epidermal growth factor receptor-tyrosine kinase inhibitorsnon-small cell lung canceradverse eventmanagement
相关
加载中…
  • Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials
    Lu, Hong-Lian; Jie, Guang-Ling; Wu, Yi-Long*EXPERT OPINION ON EMERGING DRUGS, 2022, 27(2): 111-126.
  • Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer
    Shi, Xiaoshun; Dong, Xiaoying; Zhai, Jianxue; Liu, Xiguang; Lu, Di; Ni, Zhen; Wu, Hua; Cai, Kaican*Frontiers in Oncology, 2021, 11: 608608.被引 5
  • Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials
    Li, Dailong; Yao, Ling; Xu, Lu; Li, Wanqiang; Che, Yuan*Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2022, 101(48).
查看全部 →

发表信息

论文状态
公开发表
期刊
Expert Opinion On Drug Safety
发表日期
2020-05-03
卷期
第 19 卷, 第 5 期
页码
589-599
DOI
10.1080/14740338.2020.1753697
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
2区
成果收录
SCIE

作者

  • Z

    Zhou, Jia-Ying (第一作者)

  • L

    Liu, Si-Yang

查看全部 3 位作者收起作者
  • W

    Wu, Yi-Long (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417